Cargando…

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

Detalles Bibliográficos
Autores principales:	Osborne, R. J., Malik, S. T., Slevin, M. L., Harvey, V. J., Spona, J., Salzer, H., Williams, C. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1988
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246673/ https://www.ncbi.nlm.nih.gov/pubmed/3348944

Ejemplares similares

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Correction: Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
por: Canney, P. A., et al.
Publicado: (1988)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

The switcher and the scheduler
por: Arnault, C, et al.
Publicado: (1987)

Morphological and Immunohistochemical Study of Ovarian and Tubal Dysplasia Associated with Tamoxifen
por: Chene, G., et al.
Publicado: (2014)

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
por: McClay, E. F., et al.
Publicado: (1994)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy
por: Maji, Ruma, et al.
Publicado: (2014)

Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study
por: Pala, Şehmus, et al.
Publicado: (2015)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

PROOF: the Parallel ROOT Facility. Scheduling and Load-balancing
por: Iwaszkiewicz, J, et al.
Publicado: (2007)

An epigenomic approach to therapy for tamoxifen-resistant breast cancer
por: Feng, Qin, et al.
Publicado: (2014)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Low‐Dose Tamoxifen Induces Significant Bone Formation in Mice
por: Xie, Zhihui, et al.
Publicado: (2021)

Tamoxifen-associated polypoid endometriosis mimicking an ovarian neoplasm
por: Choi, In Ho, et al.
Publicado: (2015)

Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer
por: Moin, Afrasim, et al.
Publicado: (2021)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
por: Bratherton, D. G., et al.
Publicado: (1984)

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.
por: Thompson, P., et al.
Publicado: (1991)

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
por: Cohen, I., et al.
Publicado: (1994)

Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes
por: Rondón-Lagos, Milena, et al.
Publicado: (2016)

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
por: Lee, Seul, et al.
Publicado: (2018)

Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice
por: Fong, Cora J, et al.
Publicado: (2007)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy
por: Mourits, M J, et al.
Publicado: (2002)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
por: Braal, C. Louwrens, et al.
Publicado: (2021)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
por: Gore, M. E., et al.
Publicado: (1997)

Programación de bases de datos con MySQL y PHP /
por: Spona, Helma
Publicado: (2010)

Solid Self-Nano Emulsifying Nanoplatform Loaded with Tamoxifen and Resveratrol for Treatment of Breast Cancer
por: Shrivastava, Nupur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gmm1dvi0s0ci53gk1r1711ti48